Sunday, February 9, 2025

CATEGORY

Merck (MSD)

KEYTRUDA Gains New Indication for Early-Stage NSCLC in China

Key TakeawaysKEYTRUDA’s approval is likely to become a standard care component for early-stage NSCLC in China. Enhanced survival rates may lead to increased...

Merck Secures Exclusive License for Groundbreaking LM-299 Antibody

Key TakeawaysMerck's investment underscores a commitment to expanding its oncology pipeline with dual-action antibodies. LM-299’s bispecific nature may offer superior efficacy compared to...

Merck’s DOR/ISL Achieves Success in Phase 3 HIV Trials

Key Takeaways • DOR/ISL offers a once-daily, two-drug regimen simplifying treatment protocols for HIV-1 patients. • The non-inferiority results support DOR/ISL as a viable alternative to...

Merck Secures Exclusive License for HS-10535 with Hansoh Pharma

Key TakeawaysHS-10535 could offer superior cardiometabolic outcomes compared to existing treatments. The partnership enables Merck to expand its global footprint in metabolic disease...

Merck Achieves 100% Complete Response in DLBCL Trial with Zilovertamab Vedotin

Key TakeawaysHigh efficacy demonstrated by 100% complete response at 1.75 mg/kg dose All patients at the recommended dose completed the trial without discontinuation ...

WINREVAIR Successfully Reduces Morbidity in Severe PAH, Study Ends Early

key TakeawaysWINREVAIR’s rapid efficacy may redefine treatment protocols for severe PAH. Early trial termination reflects the drug’s substantial benefit over standard therapies. Comparable...

Merck Showcases Breakthrough Hematologic Research at ASH 2024

Merck is set to present significant advancements in hematologic malignancies at the upcoming American Society of Hematology Annual Meeting, highlighting both approved and investigational...

Merck Launches First Oral Therapy for VHL-Related Tumors in China

Merck has secured approval from China's National Medical Products Administration (NMPA) for WELIREG (belzutifan), marking a significant advancement in the treatment of von Hippel-Lindau...

KEYTRUDA’s Dual Approval Shakes Up Gynecologic Cancer Treatments in Europe

In a significant stride for cancer treatment, Merck's KEYTRUDA has received European Commission approval for two new indications in gynecologic cancers. This milestone marks...

Clesrovimab Demonstrates Significant Efficacy in Reducing RSV Hospitalizations in Infants

Merck has made a promising announcement about its investigational monoclonal antibody, clesrovimab, which has shown remarkable results in reducing cases of respiratory syncytial virus...

Gilead and Merck’s New HIV Treatment Regimen Shows Promising Results

Key TakeawaysGilead Sciences and Merck's investigational combination of islatravir and lenacapavir demonstrates comparable effectiveness to daily HIV treatments in maintaining viral suppression. The...

Exelixis and Merck Forge Collaboration to Advance Cancer Treatment

Key TakeawaysExelixis and Merck have entered a clinical development collaboration to evaluate Exelixis' zanzalintinib in combination with KEYTRUDA® (pembrolizumab) for head and neck...

Chronic Lymphocytic Leukemia Treatment Expanded as Pharmac Broadens Access to Cancer Medications in New Zealand

Key TakeawaysChronic lymphocytic leukemia patients in New Zealand will benefit from expanded access to the chemotherapy drug bendamustine, offering new treatment options for...

Merck Presents Long-Term Data for Tulisokibart in IBD

Key TakeawaysMerck showcases long-term efficacy of tulisokibart in ulcerative colitis and Crohn’s disease at UEG Week 2024. Phase 2 data show sustained treatment...

Merck Expands Pipeline with CN201 B-Cell Therapy Acquisition

Key TakeawaysMerck acquires CN201, a bispecific antibody targeting B-cell malignancies and autoimmune diseases. CN201 shows promise in treating relapsed B-cell hematologic malignancies, such...

Latest news